文献速递妇科

子宫内膜取样中ARID1A表达缺失与子宫内膜癌风险相关

Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2018-07-04

研究评估ARID1A免疫组化在子宫内膜取样中预测复杂不典型增生(CAH)患者合并子宫内膜样癌(EEC)的价值。队列A中,取样标本ARID1A缺失者后续子宫切除标本94%发现EEC,而表达保留者仅15%(P<0.0001)。队列B中45例CAH/EEC并存者,EEC成分ARID1A缺失14例(31%),其中50%的CAH成分也缺失。

要点

  • 子宫内膜取样中ARID1A缺失与后续子宫切除标本发现EEC风险显著相关(94% vs 15%)。
  • CAH/EEC并存标本中,EEC成分ARID1A缺失率31%,其中半数CAH成分亦缺失。
  • ARID1A免疫染色或可作为预测CAH患者合并EEC的组织生物标志物。

核心结论

  • ARID1A免疫染色或与CAH患者的恶性转化及并存EEC相关。
  • 作者认为需进一步研究确定ARID1A表达作为组织生物标志物的潜在效用。

研究设计与样本

  • 队列A:评估子宫内膜取样标本显示CAH者的ARID1A免疫反应性,分析其与后续子宫切除标本中EEC的相关性。
  • 队列B:评估子宫切除标本中CAH与EEC并存者的ARID1A免疫反应性,评估两种成分中表达的一致性。

主要发现

  • 队列A中,因术前诊断为CAH行子宫切除术的患者,31%的子宫内膜取样标本存在ARID1A免疫反应性缺失。
  • 队列A中,取样标本ARID1A缺失者后续子宫切除标本94%发现EEC,而表达保留者仅15%(P < 0.0001)。
  • 未观察到ARID1A表达与人口学特征之间的关联。
  • 队列B中,45例子宫切除标本CAH/EEC并存者,14例(31%)的EEC成分完全缺失ARID1A表达。
  • 队列B中,上述14例中50%的CAH成分也缺失ARID1A免疫反应性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Inactivating somatic mutations of ARID1A, a chromatin remodeling gene, are common in endometrioid endometrial carcinoma (EEC) but rare in complex atypical hyperplasia (CAH). Our objectives were to determine the clinical significance of ARID1A loss during tumor progression from CAH to EEC and to assess its role as a predictive cancer biomarker. METHODS: In cohort A, ARID1A immunoreactivity was evaluated in endometrial sampling (biopsy/curettage) specimens showing CAH to determine whether ARID1A expression correlates with the presence of EEC at subsequent hysterectomy. In cohort B, ARID1A immunoreactivity was evaluated in the hysterectomy specimens with concurrent CAH and EEC to assess for the concordance of ARID1A expression in both components. RESULTS: In cohort A, loss of ARID1A immunoreactivity was identified in the endometrial sampling specimen of 31% of patients undergoing hysterectomy for a preoperative diagnosis of CAH. EEC was identified in the hysterectomy specimen of 94% of patients with loss of ARID1A in the endometrial sampling specimen while only 15% of patients with retained ARID1A expression (P < 0.0001). No association was observed between ARID1A expression and demographic characteristics. In cohort B, 14 (31%) of 45 patients with concurrent CAH/EEC in their hysterectomy specimens had complete loss of ARID1A expression in the EEC components. Among these 14 patients, 50% also had loss of ARID1A immunoreactivity in the CAH component. CONCLUSIONS: ARID1A immunostaining may correlate with malignant transformation and the presence of concurrent EEC in patients with CAH identified at pre-hysterectomy endometrial sampling. Further investigation to determine the potential utility of ARID1A expression as a tissue biomarker is warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yen TT, Miyamoto T, Asaka S, et al. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. Gynecol Oncol. 2018. PMID: 30126589. doi:10.1016/j.ygyno.2018.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。